Register now for virtual pitches January 10, 13 + 14!
While some are still recovering from the holiday break and slogging through snow and ice, VisionTech has just announced a flurry of virtual pitch events set for the second week of January. On-deck for a shot at capital are current portfolio company NuvOx Therapeutics and two newcomers, SinuSauna and NICKLpass. (Dates, times, previews and registration info below.)
All three presenting company CEOs will get a full hour to pitch in a live, virtual format that gives VisionTech investors from across Indiana and the country to interact with the CEOs and get an insider’s look at the opportunity. VisionTech Executive Director Ben Pidgeon tested the single company pitch event format in 2024 and made the decision to go to it fulltime in 2025.
“Having more time for investors to really dive in and ask questions of the CEOs following the formal presentation is a huge benefit,” Pidgeon says. “Our investors want to go beyond the pitch deck and uncover compelling reasons to invest in early growth companies. The single pitch company format does that.”
VisionTech virtual pitch events are open to member-investors and pre-registered guests. Pidgeon encourages those interested in potentially joining VisionTech’s vibrant angel network to experience a pitch event firsthand. Guests may register by contacting Pidgeon. “As one of the Midwest’s most active angel groups, our deal flow, due diligence process, and opportunities are second to none.”
Here is VisionTech’s January Virtual Pitch Lineup:
NuvOx Therapeutics
Rong Wang, CEO + President
Friday, January 10, 9 a.m. ET
Website
A VisionTech portfolio company since 2023, NuvOx returns for a follow-on round. The clinical stage pharmaceutical company has developed first-in-class oxygen therapeutics and is currently raising a $7 million round in two tranches. The first tranche of $3 million will support three active clinical trials: two Phase IIb trials (glioblastoma and stroke) and a Phase Ib (respiratory distress). NuvOx has already successfully completed two Phase IIa trials in Glioblastoma and stroke.
NuvOx’s lead therapeutic, NanO₂, has a unique mechanism of action that improves the flow of oxygen from lungs to blood and from blood to tissue. Over 30 animal studies have shown therapeutic effect in seven different indications where hypoxia is life threatening. This includes acute hypoxemic respiratory failure, traumatic brain injury, myocardial infarction (heart attack), and hemorrhagic shock.
NuvOx was co-founded by serial entrepreneur Evan Unger, MD, a board-certified radiologist and Professor Emeritus of Medical Imaging at the University of Arizona. His first biotech company, ImaRx Pharmaceutical, developed three FDA-approved drugs and was acquired by DuPont. His second company, ImaRx Therapeutics, went public. NuvOx’s has a highly experienced leadership team. Learn more.
SinuSauna
Nancy Wright, CEO
Monday, January 13, 12 noon ET
Website
SinuSauna is the first respiratory wellness solution invented by physicians that uses the power of heated dry air therapy to counter nasal congestion. Backed by clinical studies that support the benefits of heated, dry air to proactively limit germs before they build up, SinaSauna is a soothing, effective alternative to nasal irrigation products. Users enjoy nasal wellness benefits without drugs, chemicals, mess, and discomfort.
SinuSauna is the first commercially available product of Respiratory Health Technologies, launched with the support of Boomerang Ventures, an Indianapolis-based venture fund and studio. The product is available now on Amazon and is generating revenue. SinuSauna seeks to raise $140,000 that remains in a $700,000 pre-seed round to accelerate commercialization.
NICKLpass
Sumorwuo Zaza, CEO
Tuesday, January 14, 12 noon
Website
Companies and their teams rely on news sites to stay on top of breaking news and critical trends. The challenge is most news sites require subscriptions, which can be cost prohibitive. There are very few tech-enabled ways for companies to purchase and manage enterprisewide subscriptions. NICKLpass is the solution, a digital platform that provides access to 100-plus (and growing) paid news subscriptions in one account with one login and without passwords or paywalls for an entire team. The savings are significant: up to 50% off retail subscriptions.
NICKLpass’s client list is impressive and includes Ford, Microsoft, and VISA where senior executives are active users. Its leadership and advisory teams have deep media and technology experience from places like HuffPost, CNN, Thomson Reuters, Google, CBS, iHeartRadio, and The New York Times. The board includes the founder of women.com which IPO’d and was sold to Hearst.
NICKLpass is raising $1.25 million primarily for business development and ongoing product development. The goal is to break even by mid 2025 and fund company continued growth through earnings or a Series A.
Registration is required to attend any or all of VisionTech’s January virtual pitch events and digitally meet the CEOs. VisionTech member-investors should email thensley@visiontech-partners.com to register. Guests should reach out to bpidgeon@visiontech-partners.com